好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Upper Cervical Cord Atrophy Predicts Disability Through Motor Clinical Impairment in Multiple Sclerosis Patients
Neuro-rehabilitation
P8 - Poster Session 8 (5:30 PM-6:30 PM)
11-017
To understand if the association between upper cervical cord atrophy and disability is direct or indirectly mediated by motor clinical impairment in multiple sclerosis (MS) patients.
MS is one of the most common causes of neurological disability in young adults and it is characterized by several motor symptoms, among which, impaired walking capacity and manual dexterity. In MS, structural damage of the cervical spinal cord is frequent and already present from early disease stages. Mean upper cervical cord area (MUCCA) measurement can be used to quantify cervical cord atrophy and it seem to be directly associated with disability, walking capacity and manual dexterity in MS.

In this cross-sectional study, expanded disability status scale (EDSS), timed 25-foot walk (T25FW), six-minute walk test (6MWT), timed up and go (TUG) test, finger tapping (FT), nine-hole peg test (9HPT) and MUCCA measure (derived from 3D T1-weigthed brain images) were collected for 60 MS patients and 36 healthy controls (HC). In MS, the associations between MUCCA and clinical variables were explored. Then focusing on the relation between MUCCA and EDSS, we performed a mediation analysis to understand the potential role of clinical impairment as mediator.

In MS, lower MUCCA was associated with higher EDSS (R=-0.47, p<0.001) and lower values of inverse TUG (R=0.41, p=0.002), inverse T25FW (R=0.38, p=0.003), 6MWT (R=0.38, p=0.004) and FT (R=0.39, p=0.003). Within the mediation model, there was no direct effect of MUCCA on EDSS (β=-0.02, 95%CI [-0.05;0.01]), but there was a significant total indirect effect acting through T25FW, 6MWT, TUG and FT (β=-0.06, 95%CI [-0.10;-0.03]). Singularly, none of the clinical impairment seems to act as mediator.

In MS, in accordance with the ICF system, upper cervical cord atrophy predicts disability, but this relation is indirectly mediated by the overall impact of impairment in walking capacity, balance and manual dexterity domains.

Authors/Disclosures
Monica Margoni
PRESENTER
Monica Margoni has received research support from MAGNIMS. Monica Margoni has received research support from Merck-Serono. Monica Margoni has received research support from Sanofi-Genzyme.
Matteo Albergoni, PT (Ospedale San Raffaele SRL (VAT: IT 07636600962)) Dr. Albergoni has nothing to disclose.
CHIARA DALLARI Miss DALLARI has nothing to disclose.
Paola Valsasina Paola Valsasina has nothing to disclose.
Martina Rubin, MD (San Raffaele Hospital) Dr. Rubin has nothing to disclose.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Maria A. Rocca (Neuroimaging Research Unit) Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.